Skip to main content
SpringerLink
Log in

Local Immunotherapy for Basal Cell Carcinoma with Interferon

  • Chapter
  • First Online:
Basal Cell Carcinoma

  • 1017 Accesses

Abstract

Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer (NMSC) in the United States, accounting for 80% of (NMSC) [1]. Treatment options include local destruction such as curettage with or without electrodesiccation, cryosurgery, radiation, and surgical interventions including Mohs micrographic surgery (MMS) and excisional surgery with 4 mm margins. In many instances these methods can give a complete response rate (CRR) of 90–99%. Along with consideration of CRR, the choice of intervention used to eliminate BCC should include patient preference. This may encompass factors including the patient’s age and health, cost, the original tumor size and type, location, potential for postoperative anatomic dysfunction, and posttreatment cosmesis as well as efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146:283–7.

    Article  Google Scholar 

  2. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47:1–17; quiz 8–20.

    Article  Google Scholar 

  3. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67.

    Article  Google Scholar 

  4. Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–901.

    Article  CAS  Google Scholar 

  5. Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol. 1986;15:437–43.

    Article  CAS  Google Scholar 

  6. Cornell RC, Greenway HT, Tucker SB, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol. 1990;23:694–700.

    Article  CAS  Google Scholar 

  7. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989;15:315–28.

    Article  CAS  Google Scholar 

  8. Tucker SB, Polasek JW, Perri AJ, Goldsmith EA. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol. 2006;54:1033–8.

    Article  Google Scholar 

  9. Healsmith MF, Berth-Jones J, Fletcher A, Graham-Brown RA. Treatment of basal cell carcinoma with intralesional interferon alpha-2b. J R Soc Med. 1991;84:524–6.

    Article  CAS  Google Scholar 

  10. Arpey CJ, Annest NM, Tucker SB, Rapini RP, MacFarlane DF. Intralesional and perilesional treatment of skin cancers. In: MacFarlane DF, editor. Skin cancer management: a practical approach. New York: Springer New York; 2010. p. 57–77.

    Google Scholar 

  11. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2:466–74.

    Article  CAS  Google Scholar 

  12. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia. 2001;15:1022–32.

    Article  CAS  Google Scholar 

  13. Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol. 2014;26:38–47.

    Article  CAS  Google Scholar 

  14. Showalter A, Limaye A, Oyer JL, et al. Cytokines in immunogenic cell death: applications for cancer immunotherapy. Cytokine. 2017;97:123–32.

    Article  CAS  Google Scholar 

  15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  CAS  Google Scholar 

  16. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol. 2005;152:43–51.

    Article  CAS  Google Scholar 

  17. Laner-Plamberger S, Wolff F, Kaser-Eichberger A, et al. Hedgehog/GLI signaling activates suppressor of cytokine signaling 1 (SOCS1) in epidermal and neural tumor cells. PLoS One. 2013;8:e75317.

    Article  CAS  Google Scholar 

  18. Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene. 2001;20:198–208.

    Article  CAS  Google Scholar 

  19. Pellegrini C, Orlandi A, Costanza G, et al. Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments. PLoS One. 2017;12:e0183415.

    Article  Google Scholar 

  20. Nardinocchi L, Sonego G, Passarelli F, et al. Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. Eur J Immunol. 2015;45:922–31.

    Article  CAS  Google Scholar 

  21. Fischer-Stabauer M, Boehner A, Eyerich S, et al. Differential in situ expression of IL-17 in skin diseases. Eur J Dermatol. 2012;22:781–4.

    CAS  PubMed  Google Scholar 

  22. Zhang S, Zheng M, Kibe R, et al. Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. FASEB J. 2011;25:2387–98.

    Article  CAS  Google Scholar 

  23. Zheng SJ, Lamhamedi-Cherradi SE, Wang P, Xu L, Chen YH. Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes. 2005;54:1423–8.

    Article  CAS  Google Scholar 

  24. Okuda Y, Okuda M, Bernard CC. Regulatory role of p53 in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2003;135:29–37.

    Article  CAS  Google Scholar 

  25. Ak P, Levine AJ. p53 and NF-kappaB: different strategies for responding to stress lead to a functional antagonism. FASEB J. 2010;24:3643–52.

    Article  CAS  Google Scholar 

  26. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol. 2008;10:611–8.

    Article  CAS  Google Scholar 

  27. Buechner SA, Wernli M, Harr T, Hahn S, Itin P, Erb P. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest. 1997;100:2691–6.

    Article  CAS  Google Scholar 

  28. Li C, Chi S, He N, et al. IFNalpha induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling. Oncogene. 2004;23:1608–17.

    Article  CAS  Google Scholar 

  29. Wang XY, Zhang R, Lian S. Aberrant expression of Fas and FasL pro-apoptotic proteins in basal cell and squamous cell carcinomas. Clin Exp Dermatol. 2011;36:69–76.

    Article  Google Scholar 

  30. Knop J. Immunologic effects of interferon. J Invest Dermatol. 1990;95:72S–4S.

    Article  CAS  Google Scholar 

  31. Buechner SA. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression. J Am Acad Dermatol. 1991;24:731–4.

    Article  CAS  Google Scholar 

  32. Grob JJ, Collet AM, Munoz MH, Bonerandi JJ. Treatment of large basal-cell carcinomas with intralesional interferon-alpha-2a. Lancet. 1988;1:878–9.

    Article  CAS  Google Scholar 

  33. Stenquist B, Wennberg AM, Gisslen H, Larko O. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery. J Am Acad Dermatol. 1992;27:65–9.

    Article  CAS  Google Scholar 

  34. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722–33.

    Article  Google Scholar 

  35. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152:939–47.

    Article  CAS  Google Scholar 

  36. Huang SJ, Hijnen D, Murphy GF, et al. Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009;129:2676–85.

    Article  CAS  Google Scholar 

  37. Tong Y, Tucker SB. Normal mouse skin lymphocyte, Langerhans cell, and keratinocyte responses to intradermal injections of interferon-alpha and interferon-gamma. J Interf Cytokine Res. 1995;15:235–41.

    Article  CAS  Google Scholar 

  38. Turan A, Saricaoglu H, Baskan EB, Toker SC, Tunali S. Treatment of infiltrating basal cell carcinoma with the combination of intralesional IFNalpha-2b and topical imiquimod 5% cream. Int J Dermatol. 2009;48:214–5.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas MD Anderson Cancer Center, Department of Dermatology, Division of Internal Medicine, Houston, TX, USA

    Hung Q. Doan

  2. University of Texas McGovern Medical School at Houston, Department of Dermatology, Houston, TX, USA

    Stephen B. Tucker

Authors
  1. Hung Q. Doan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen B. Tucker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen B. Tucker .

Editor information

Editors and Affiliations

  1. The University of Texas MD Anderson Cancer Center, Departments of Dermatology and Head and Neck Surgery, Mohs Surgery Center, Houston, TX, USA

    Michael R. Migden

  2. The University of Texas MD Anderson Cancer Center, Department of Dermatology, Houston, TX, USA

    Leon Chen

  3. University of Texas McGovern Medical School at Houston, Department of Dermatology, Houston, TX, USA

    Sirunya Silapunt

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Doan, H.Q., Tucker, S.B. (2020). Local Immunotherapy for Basal Cell Carcinoma with Interferon. In: Migden, M., Chen, L., Silapunt, S. (eds) Basal Cell Carcinoma. Springer, Cham. https://doi.org/10.1007/978-3-030-26887-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-26887-9_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-26886-2

  • Online ISBN: 978-3-030-26887-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation